HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Aug.3)-Medical Device Valuation Repair,Deal on IBI363,WuXi AppTec Placement

China Healthcare Weekly (Aug.10)-Trump Plans Drug Tariff, Biosimilar VBP, BeiGene's Headwind in 25Q2

Pre-IPO Guangzhou Innogen Pharmaceutical Group (PHIP Updates) - Some Points Worth the Attention

China TCM (570.HK) - About the 25H1 Profit Warning and the Outlook

Pre-IPO Ab&B Bio-Tech: Commercialization May Be Lower than Expected, Thereby Dragging Down Valuation

China Healthcare Weekly (Jul.27)-The Turning Point of Tigermed and CRO, Everest Medicines’ Placement

What Happens to China Healthcare? - The Soaring Shares, the Turning Point, and the Top Picks

Equity Capital Markets

<ul>
<li>Quadrivalent subunit influenza vaccine has been approved for market launch, but performance deteriorated due to product returns and provision for impairment of inventories.Fierce competition has intensified the pressure on profits.</li>
<li>Core founding shareholders have no background in vaccine R&amp;D.Ab&amp;B lags behind in terms of R&amp;D capabilities/forward-looking vision, leading to insufficient depth of pipeline layout and a decline in future competitiveness.</li>
<li>After Series B financing, post-money valuation reached RMB4.2 billion. We think <a href="https://www.smartkarma.com/entities/ab-b-bio-tech-co-ltd" target="_blank" data-smartkarma-citation="entities:44278:1" rel="noopener">Ab&amp;B Bio-Tech (ABB HK)</a>’s valuation should be lower than CanSino, but would be higher than <a href="https://www.smartkarma.com/entities/aim-vaccine-co-ltd" target="_blank" data-smartkarma-citation="entities:33778:1" rel="noopener">AIM Vaccine (6660 HK)</a>. </li>
</ul>


Quadrivalent subunit influenza vaccine has been approved for market launch, but performance deteriorated due to product returns and provision for impairment of inventories.Fierce competition has intensified the pressure on profits.
Core founding shareholders have no background in vaccine R&amp;D.Ab&amp;B lags behind in terms of R&amp;D capabilities/forward-looking vision, leading to insufficient depth of pipeline layout and a decline in future competitiveness.
After Series B financing, post-money valuation reached RMB4.2 billion. We think Ab&amp;B Bio-Tech (ABB HK)’s valuation should be lower than CanSino, but would be higher than AIM Vaccine (6660 HK). 


Pre-IPO Ab&B Bio-Tech (PHIP Updates) - Some Points Worth the Attention